Hologic (NASDAQ:HOLX) Updates FY19 Earnings Guidance

Hologic (NASDAQ:HOLX) issued an update on its FY19 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $2.60-2.65 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.44. The company issued revenue guidance of $3.4-3.5 billion, compared to the consensus revenue estimate of $3.35 billion.Hologic also updated its Q1 guidance to $0.59-0.61 EPS.

Shares of NASDAQ HOLX traded up $0.36 during trading on Friday, hitting $46.56. The company had a trading volume of 2,275,800 shares, compared to its average volume of 1,801,821. The firm has a market capitalization of $12.86 billion, a P/E ratio of 20.30, a price-to-earnings-growth ratio of 2.03 and a beta of 0.76. The stock has a 50 day simple moving average of $48.87 and a 200 day simple moving average of $48.00. The company has a debt-to-equity ratio of 1.27, a quick ratio of 1.11 and a current ratio of 1.57. Hologic has a 12 month low of $37.48 and a 12 month high of $52.19.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $0.65 earnings per share for the quarter, meeting the consensus estimate of $0.65. The business had revenue of $865.80 million during the quarter, compared to analysts’ expectations of $846.54 million. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.58 EPS. As a group, analysts predict that Hologic will post 2.64 EPS for the current year.

HOLX has been the subject of several research analyst reports. Argus raised their price target on Hologic to $62.00 and gave the company a buy rating in a report on Wednesday, August 14th. Piper Jaffray Companies raised their price target on Hologic from $49.00 to $59.00 and gave the company an overweight rating in a report on Thursday, August 1st. Bank of America upgraded Hologic from a neutral rating to a buy rating and lifted their target price for the stock from $54.00 to $59.00 in a report on Thursday, September 26th. BTIG Research reiterated a buy rating and issued a $52.00 target price on shares of Hologic in a report on Thursday, August 1st. Finally, ValuEngine cut Hologic from a hold rating to a sell rating in a report on Friday, October 25th. Three analysts have rated the stock with a sell rating, four have assigned a hold rating and six have issued a buy rating to the company. Hologic currently has a consensus rating of Hold and a consensus price target of $51.48.

In other news, insider Peter J. Valenti III sold 7,766 shares of Hologic stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $49.14, for a total value of $381,621.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.90% of the stock is currently owned by insiders.

Hologic Company Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Earnings History and Estimates for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.